Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU)-Reference-Cited by-同舟云学术

Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU)

Published:2020 Issue:2 Volume:5 Page:e000666
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Casali Paolo G.,Trama Annalisa^ORCID

Funder

European Union’s Health Programme

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference5 articles.

1. Rare cancers are not so rare: the rare cancer burden in Europe;Gatta;Eur J Cancer,2011

2. Food and Drug Administration. Available: https://www.ecfr.gov/cgi-bin/textidx?c=ecfr&SID=51cf70689d51f0ea4147c0a8ac649321&rgn=div5&view=text&node=21:5.0.1.1.6&idno=21

3. Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors;Ferrari;Eur J Cancer,2019

4. Orphan drug regulation: a missed opportunity for children and adolescents with cancer;Vassal;Eur J Cancer,2017

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preserving momentum on next-generation sequencing for head and neck squamous cell carcinoma;Annals of Oncology;2024-10

2. Operational description of rare diseases: a reference to improve the recognition and visibility of rare diseases;Orphanet Journal of Rare Diseases;2024-09-11

3. Paediatric very rare tumours registration and management in European countries with low health expenditure average rates;Clinical and Translational Oncology;2024-09-03

4. High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks;Cell Death Discovery;2024-08-26

5. Development and validation of survival nomograms for patients with anaplastic thyroid carcinoma: a SEER Program-based study;2024-08-07